AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 14, 2026, 12:00 PM ET Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek 2026 Annual Meeting Headline · Source: company release
U.S. listed: $AMLXBiotech · Endocrine and neurological careExecution and funding risks

AMLX Stock Hub: Amylyx Pharmaceuticals News, Avexitide and Clinical Development

Amylyx reported $768.1 million in September cash and securities after its August offering. On November 14 it released detailed Phase 3 LUCIDITY results for avexitide, presented as a late-breaking oral at ObesityWeek on November 15, the day of its investor KOL event; it targets an NDA submission by year-end 2026 and a potential 2027 launch, if approved.

Last updated: November 17, 2026Financial period: Quarter and nine months ended September 30, 2026Currency: U.S. dollars
Full research report · PDF
Amylyx Pharmaceuticals, Inc. research updated November 15, 2026
29 pages. Detailed Phase 3 LUCIDITY results and the ObesityWeek presentation, Q3 results, financing and runway, the avexitide filing timeline, price chart to the November 13 close, Health Score 4.25. Personal use only: redistribution prohibited.
Get the report (PDF)
Next company-guided milestone
Avexitide NDA submission · targeted by year-end 2026

Amylyx targets submission of the avexitide New Drug Application for post-bariatric hypoglycemia by year-end 2026 and is preparing for a potential commercial launch in 2027, if approved, according to its November 14 release; the deck of its November 15 investor event closes with “NDA Submission on Track for Year-end 2026.” The submission is a company target, not a scheduled event: FDA acceptance, review and approval would be separate steps, and no FDA decision date has been announced. LUCIDITY results release · November 15 investor event deck · Events and presentations

Before that: on November 15 the LUCIDITY results were the subject of a late-breaking oral presentation at ObesityWeek in Washington, D.C. (ObesityWeek presentation slides), and Amylyx’s investor KOL event on the results was set for 11:45 a.m. ET the same day, in person and by webcast with a 90-day replay (investor event deck · event announcement). On November 14 Amylyx released detailed LUCIDITY results, including a 55% reduction versus placebo in the composite rate of Level 2 and Level 3 hypoglycemic events (0.55 versus 1.24 events per week, p=0.0000034) and all prespecified, multiplicity-controlled secondary event-rate endpoints met (LUCIDITY results release). Management held a fireside chat at the Guggenheim Healthcare Innovation Conference in Boston on November 9 at 9:30 a.m. ET, and a fireside chat at the Stifel 2026 Healthcare Conference in New York was scheduled for November 10 at 3:20 p.m. ET (Investor conferences). Q3 results were reported before the market opened on November 5, followed by a conference call at 8:00 a.m. ET, with cash, equivalents and marketable securities of $768.1 million at September 30 (Q3 2026 results release).
Amylyx Pharmaceuticals AMLX daily stock chart
Daily chart $AMLX. The chart link is an affiliate link. Interactive chart with bull and bear scenarios on JC Just Charts →

AMLX stock at a glance

Chart analysis · JC
Technical chart analysis of $AMLX with bull and bear scenarios on JC Just Charts.
LUCIDITY primary result
−55%
Composite Level 2 and 3 event rate versus placebo: 0.55 versus 1.24 events per week, p=0.0000034.
Source
Q3 GAAP net loss
$45.489M
Quarter ended September 30.
Source
Cash and marketable securities
$768.132M
At September 30, after the August offering.
Source
Nine-month operating cash use
$101.980M
Through September 30.
Source
Common shares outstanding
128,562,904
October 26, 2026, Form 10-Q cover.
Source
August offering net proceeds
$544.6M
Approximate, after offering expenses.
Source
Avexitide NDA
By year-end 2026
Company submission target.
Source

Where Amylyx Pharmaceuticals stands now

Amylyx reported Q3 2026 results on November 5, 2026. Cash, cash equivalents and marketable securities were $768.1 million at September 30, up from $250.8 million at June 30, reflecting net proceeds of about $544.6 million from the August offering. The quarterly net loss was $45.5 million, or $0.38 per share, as R&D expenses rose to $28.4 million and SG&A to $21.3 million with pre-commercial hiring. The company says it remains on track to submit the avexitide NDA by the end of 2026 and describes a potential 2027 launch, if approved; it also completed enrollment of Cohort 3 and began Cohort 4 of the Phase 1 LUMINA trial of AMX0114 in ALS. Q3 2026 results

On November 14, 2026 Amylyx released the results of the 16-week double-blind treatment period of the Phase 3 LUCIDITY trial of avexitide, an investigational, first-in-class GLP-1 receptor antagonist, in post-bariatric hypoglycemia (PBH) after Roux-en-Y gastric bypass, which were presented as a late-breaking oral at ObesityWeek on November 15. Avexitide reduced the composite rate of SMBG-confirmed Level 2 and adjudicated Level 3 hypoglycemic events by 55% versus placebo (least squares mean of 0.55 versus 1.24 events per week, p=0.0000034). All prespecified, multiplicity-controlled secondary event-rate endpoints were met: SMBG-confirmed Level 2 events fell 63% (p=0.0000032), adjudicated Level 3 events 47% (p=0.0016) and CGM-detected Level 2 events 42% (p=0.00016) versus placebo. Within each arm, events decreased 72.9% from baseline on avexitide and 37.8% on placebo (p=0.000034 for the difference). The trial enrolled 78 adults at 21 U.S. sites, randomized 3:2 to avexitide 90 mg subcutaneously once daily or placebo; 45 of 47 avexitide and 28 of 31 placebo participants completed the double-blind period, and all eligible participants entered the 32-week open-label extension, which remains ongoing. Treatment-emergent adverse events were primarily gastrointestinal and injection-site related and generally mild to moderate; there were no deaths and no treatment-related serious adverse events. The ObesityWeek slides add a rate ratio of 0.45 (95% CI 0.32–0.63) for the primary endpoint, treatment-emergent adverse events in 83% of avexitide participants (39 of 47) versus 63% on placebo (19 of 30), and one treatment-emergent serious adverse event in each arm, none related to study drug. “These positive data, together with positive results from five prior trials of avexitide in PBH, support the potential for avexitide to change practice for this debilitating condition,” said Camille L. Bedrosian, MD, Chief Medical Officer. Marilyn Tan, MD, the trial’s Principal Investigator and Clinical Professor at the Stanford School of Medicine, noted that most participants entered the study with daily hypoglycemia symptoms. Co-CEOs Justin Klee and Joshua Cohen said the company is moving toward an NDA submission by year end and preparing for a potential 2027 launch, if approved; the deck of the November 15 investor KOL event repeats that the NDA submission is on track for year-end 2026. LUCIDITY results release · ObesityWeek presentation slides · Investor event deck · ClinicalTrials.gov NCT06747468

Execution and funding. Shares outstanding rose to 128,544,202 at September 30, 2026 after the 16,203,500-share August offering. Avexitide remains investigational; an NDA by year-end is company guidance, and neither approval nor launch is assured.

The constructive case

The detailed LUCIDITY results released on November 14 showed a 55% reduction versus placebo in the composite hypoglycemic event rate (0.55 versus 1.24 events per week, p=0.0000034), all multiplicity-controlled secondary event-rate endpoints met (reductions of 63%, 47% and 42%), more than 90% of participants completing the double-blind period, and no deaths or treatment-related serious adverse events; avexitide holds Breakthrough Therapy Designation for PBH. With $768.1 million of cash and marketable securities at September 30, the company says it can enter 2027 well funded to commercialize avexitide, if approved. Regulatory approval and commercial execution remain unproven.

The cautious case

Quarterly operating expenses rose to $49.7 million from $36.0 million a year earlier, and launch preparation adds cost before any product revenue. The August offering lifted the share count to 128,544,202 at September 30. LUCIDITY enrolled 78 participants over a 16-week double-blind period, and placebo events also fell 37.8% from baseline; the 32-week open-label extension is still ongoing. The ObesityWeek slides show treatment-emergent adverse events in 83% of avexitide versus 63% of placebo participants. Avexitide remains investigational; an NDA by year-end is company guidance, and neither approval nor the potential 2027 launch, which depends on approval, is assured.

Latest Amylyx Pharmaceuticals news

Nov 14, 2026

Amylyx Presents Phase 3 LUCIDITY Avexitide Results in Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals presented results from the Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia at the ObesityWeek 2026 Annual Meeting. The source contains only this headline.

Nov 10, 2026

Mizuho lifts Amylyx price target to $39, maintains Outperform rating

Mizuho raised its price target on Amylyx Pharmaceuticals to $39 from $38. The bank kept its Outperform rating on the stock. Analyst action reported by the press; it is the bank's view, not Merlintrader's.

Nov 5, 2026

Amylyx Pharmaceuticals reports third quarter 2026 financial results

Amylyx Pharmaceuticals reported R&D expenses of $28.4 million for the third quarter of 2026, compared to $19.9 million a year earlier. SG&A expenses were $21.3 million, compared to $16.2 million, and the net loss was $45.5 million, or $0.38 per share. Cash, cash equivalents and marketable securities were $768.1 million at September 30, 2026.

Nov 4, 2026

Amylyx Pharmaceuticals to host investor event at ObesityWeek 2026 featuring leading PBH experts

Amylyx Pharmaceuticals will host an investor event at ObesityWeek 2026. The event will feature leading PBH experts.

Nov 3, 2026

Amylyx Pharmaceuticals to participate in upcoming November investor conferences

Amylyx Pharmaceuticals will participate in two in-person investor conferences in November 2026. A fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference is scheduled for Monday, November 9, 2026, in Boston, Massachusetts. A fireside chat at the Stifel 2026 Healthcare Conference is scheduled for Tuesday, November 10, 2026, in New York City, New York. A live webcast will be available under Events and Presentations on the Company's investor website and will be available for replay for 90 days.

Nov 2, 2026

Amylyx Pharmaceuticals to report third quarter 2026 financial results on November 5, 2026

Amylyx Pharmaceuticals, Inc. will report its third quarter 2026 financial results on Thursday, November 5, 2026. Senior management will host a conference call and audio webcast to discuss the results and other company updates. The webcast will be archived and available for replay for 90 days following the event.

AMLX stock catalysts and company milestones

  • November 5, 2026 · 8 a.m. ET — Q3 financial results reported before the market opened; conference call held at 8 a.m. ET. Reported November 5
  • November 9, 2026 · 9:30 a.m. ET — Fireside chat held at the Guggenheim 3rd Annual Healthcare Innovation Conference, Boston; webcast on the investor website. Held November 9
  • November 10, 2026 · 3:20 p.m. ET — Fireside chat at the Stifel 2026 Healthcare Conference in New York was set for this date, with a live webcast and a 90-day replay. Announced November 3
  • November 14, 2026 — Detailed Phase 3 LUCIDITY results released: 55% reduction versus placebo in the composite Level 2 and Level 3 hypoglycemic event rate (p=0.0000034), all multiplicity-controlled secondary event-rate endpoints met, no deaths and no treatment-related serious adverse events. Release Released November 14
  • November 15, 2026 · 8:30 a.m. ET — LUCIDITY results presented in a late-breaking oral at ObesityWeek, Washington, D.C.; the slides are posted on the investor website. Slides Presented November 15
  • November 15, 2026 · 11:45 a.m. ET — Investor KOL event at ObesityWeek in Washington, D.C., in person and by webcast: experts on the burden of post-bariatric hypoglycemia and a review of the Phase 3 LUCIDITY results; the event deck dated November 15 is posted, and the company said the webcast would be archived for replay for 90 days. Deck November 15 · deck posted
  • By year-end 2026 — Targeted avexitide NDA submission, which the company said on November 5 remains on track, reiterated on November 14 and restated in the November 15 investor event deck. Filing, acceptance, review and approval remain separate steps; a potential 2027 launch depends on approval.
  • 2027 — Targeted IND filing for AMX0318, a long-acting GLP-1 receptor antagonist candidate now in IND-enabling studies.

Q3 2026 results and milestones · Scientific presentation and filing outlook · Investor conferences · ObesityWeek investor event · LUCIDITY results release · ObesityWeek presentation slides · Investor event deck

Bull, middle and bear scenarios

The bear case is no longer primarily “the pivotal trial fails.”

It has moved downstream toward regulatory interpretation, commercial execution and valuation.

Financial position and runway

Amylyx reported $768.132 million of cash, cash equivalents and marketable securities at September 30, 2026, against total liabilities of $33.059 million. The August 21 offering closed with the option fully exercised: 16,203,500 new shares and net proceeds of about $544.6 million. Net cash used in operating activities was $101.980 million in the first nine months of 2026. The Q3 release says the proceeds enable the company to enter 2027 well funded to commercialize avexitide, if approved; neither the release nor the 10-Q restates a dated cash-runway horizon. Shares outstanding were 128,544,202 at September 30 and 128,562,904 at October 26, 2026. The 10-Q also lists about $30.0 million of remaining unconditional purchase obligations with manufacturers, expected to be paid through 2028. Q3 2026 results · Q3 2026 Form 10-Q

September 8, 2026: The September 8 Form 8-K discloses a definitive Bachem manufacturing agreement signed that day and a September 1 Polypeptide term sheet. Amylyx will pay Polypeptide a $30 million upfront fee for capacity reservation. Minimum annual purchasing commitments start in 2028; Polypeptide supply terms remain subject to execution of a definitive agreement. Both suppliers are non-exclusive. This prepares commercial supply if avexitide is approved; it is neither approval nor evidence of product revenue, and the fee is a cash commitment rather than financing proceeds.

Primary source

Merlintrader Health Score · $AMLX

4.25out of 5
Balance / runway · 30%4.5

Cash, cash equivalents and marketable securities of $768.1 million at September 30, 2026, after about $544.6 million of net offering proceeds, against a Q3 net loss of $45.5 million and nine-month operating cash use of $102.0 million. The company says it can enter 2027 well funded to commercialize avexitide, if approved; launch spending is still ahead.

Catalyst quality · 30%5.0

LUCIDITY met its FDA-agreed primary endpoint on August 18, 2026: a 55% reduction versus placebo in the composite rate of Level 2 and Level 3 hypoglycemic events through Week 16, p=0.000003, in 78 participants. Detailed results released on November 14 showed 0.55 versus 1.24 events per week (p=0.0000034), all multiplicity-controlled secondary event-rate endpoints met, and no deaths or treatment-related serious adverse events; the results were presented as a late-breaking oral at ObesityWeek on November 15. The next company-guided milestone is the NDA submission targeted by the end of 2026, restated in the November 15 investor event deck; a submission is not an approval, and no FDA decision date exists yet.

Dilution profile · 20%3.0

The August offering issued 16,203,500 shares at $35.50. The October 26 filing-cover count was 128,562,904 shares.

Liquidity / attention · 10%4.5

The twenty completed sessions through November 13 averaged about 1.42 million shares.

Execution history · 10%3.5

Avexitide delivered a positive pivotal readout, the September 8 Form 8-K added a Bachem manufacturing agreement and a Polypeptide term sheet, on November 5 the company reiterated its year-end NDA target while LUMINA moved to Cohort 4, and on November 14 it released detailed LUCIDITY results, with 45 of 47 avexitide and 28 of 31 placebo participants completing the double-blind period, followed on November 15 by the ObesityWeek presentation and by the deck of its investor KOL event, which kept the NDA on track for year-end 2026. The record also includes the withdrawal of RELYVRIO after the PHOENIX Phase 3 failed (p=0.667) and the 2025 discontinuation of ORION in progressive supranuclear palsy.

Reassessed November 15, 2026. Weighted calculation: 4.5 × 30% + 5.0 × 30% + 3.0 × 20% + 4.5 × 10% + 3.5 × 10% = 4.25 / 5. Financial and operating resilience over twelve to eighteen months; no price target or investment recommendation.

Red flags

  • The August offering issued 16,203,500 shares, taking the count to 128,544,202 at September 30, 2026. Avexitide remains investigational; an NDA by year-end is company guidance, and neither approval nor launch is assured.
  • LUCIDITY enrolled 78 participants at 21 U.S. sites over a 16-week double-blind period; placebo events also fell 37.8% from baseline, and the 32-week open-label extension is still ongoing.
  • Company forecasts depend on execution and may change.
  • Financial balances are as of the dates shown. Later financing is listed separately.
  • Investment involves possible loss of part or all of the capital.

AMLX Stock FAQ: Amylyx Pharmaceuticals, Inc. Questions Answered

When is the next AMLX stock catalyst?

As of November 17, 2026, Amylyx’s next company-guided milestone is the submission of the avexitide NDA, targeted by year-end 2026; the company is preparing for a potential 2027 launch, if approved, and no FDA decision date has been announced. Detailed Phase 3 LUCIDITY results were released on November 14 and presented as a late-breaking oral at ObesityWeek on November 15; the deck of the November 15 investor event restates the NDA submission as on track for year-end 2026. LUCIDITY results release. ObesityWeek presentation slides. Investor event deck.

Is Amylyx’s avexitide FDA approved?

No: as of November 15, 2026, avexitide remains investigational; the company says it is moving toward an NDA submission by year end, a target restated in its November 15 investor event deck, and there is no announced FDA decision date. The FDA has granted avexitide Breakthrough Therapy Designation for post-bariatric hypoglycemia. It is a peptide GLP-1 receptor antagonist designed to reduce excessive insulin release after gastric bypass in post-bariatric hypoglycemia. Its mechanism opposes GLP-1 agonism used in weight-loss drugs. Any 2027 launch would depend on filing, review and approval. Development program and conditional 2027 launch outlook. Current filing timetable. Avexitide mechanism and development status.

How much cash does Amylyx have, and how long will it last?

Amylyx held $768.1 million in cash, cash equivalents and marketable securities at September 30, 2026, up from $250.8 million at June 30 after net proceeds of about $544.6 million from the August offering. Nine-month operating cash use was $101.980 million, and the Q3 net loss was $45.5 million. The company says the proceeds enable it to enter 2027 well funded to commercialize avexitide, if approved; the Q3 documents do not state a dated runway, and launch spending lies ahead. Q3 2026 results. Q3 2026 Form 10-Q.

Is AMLX stock at risk of dilution?

Amylyx’s August 19, 2026 financing terms included 14,090,000 common shares and an option for up to 2,113,500 additional shares. The firm offering was priced at approximately $500.2 million gross, excluding that option. With the option exercised, 16,203,500 shares were issued; the 10-Q reports 128,544,202 shares outstanding at September 30, 2026 and 128,562,904 at October 26. Future offerings and equity awards can produce further dilution. Q3 2026 Form 10-Q. Issuer filing: underwriting agreement and financing terms. Company pricing announcement.

When does Amylyx report earnings?

As of November 15, 2026, Amylyx has not announced its next earnings date. Its latest results, reported November 5, 2026, covered the quarter ended September 30, 2026. That financial update preceded the November 14 release of detailed LUCIDITY results and their presentation at ObesityWeek on November 15. Q3 results date announcement. Scientific presentation schedule. Q3 results filing.

What does Amylyx Pharmaceuticals do?

Amylyx develops treatments for endocrine and neurodegenerative diseases. Its lead candidate avexitide targets post-bariatric hypoglycemia after gastric bypass. Other investigational programs include AMX0035 for Wolfram syndrome and AMX0114 for ALS. Its former ALS product RELYVRIO was withdrawn following an unsuccessful confirmatory trial.

What did Amylyx’s LUCIDITY Phase 3 trial show?

Amylyx announced on August 18, 2026 that LUCIDITY met its primary endpoint: a 55% reduction versus placebo in the composite rate of Level 2 and Level 3 hypoglycemic events, with p=0.000003, in 78 participants with post-bariatric hypoglycemia after Roux-en-Y gastric bypass. Detailed results released on November 14, 2026 showed 0.55 versus 1.24 events per week (p=0.0000034), with all prespecified, multiplicity-controlled secondary event-rate endpoints met. Adverse events were primarily gastrointestinal and injection-site related and generally mild to moderate, with no deaths and no treatment-related serious adverse events; the 32-week open-label extension remains ongoing. Topline results and trial population. Detailed LUCIDITY results. ObesityWeek presentation slides.

Why did Amylyx withdraw RELYVRIO for ALS?

Amylyx began withdrawing RELYVRIO/ALBRIOZA in April 2024 after the confirmatory Phase 3 PHOENIX trial failed its prespecified primary and secondary endpoints. The ALS medicine had previously received approval based on earlier evidence. AMX0035’s subsequent development in Wolfram syndrome concerns a different disease and must be assessed on its own clinical evidence. Withdrawal announcement. Current Wolfram program.

Primary sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent analysis and research. It does not constitute investment advice, personalized financial advice, an investment recommendation, an offer or a solicitation to buy or sell any security. Nothing here should be interpreted as a recommendation to buy, sell, short or hold $AMLX or any other security.

Biotechnology and pharmaceutical securities can experience extreme volatility around clinical-trial results, regulatory decisions, financing, manufacturing updates and commercial launches. A successful Phase 3 trial does not guarantee NDA acceptance, FDA approval, a commercially useful label, reimbursement, market adoption or profitability.

Company statements regarding market size, development timelines, cash runway, regulatory submissions and potential commercialization are forward-looking and may prove incorrect. Figures are stated with their reference dates because cash, share counts, ownership, market prices and sentiment can change rapidly.

Retail messages express opinions and attention; they do not show clinical efficacy, a regulatory decision or commercial demand.

Merlintrader may discuss securities that the author owns, has owned, trades or may trade in the future. Such positions may change without notice and do not alter the educational nature of this content.